A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults

<p><strong>BACKGROUND:</strong> This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults.</p> <p><stron...

Full description

Bibliographic Details
Main Authors:	Wilkie, M, Satti, I, Minhinnick, A, Harris, S, Riste, M, Ramon, R, Sheehan, S, Thomas, Z, Wright, D, Stockdale, L, Hamidi, A, O'Shea, M, Dwivedi, K, Behrens, H, Davenne, T, Morton, J, Vermaak, S, Lawrie, A, Moss, P, McShane, H
Format:	Journal article
Language:	English
Published:	Elsevier 2019

Similar Items

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
by: Manjaly Thomas, Z, et al.
Published: (2019)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
by: Wajja, A, et al.
Published: (2024)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
by: Zita-Rose Manjaly Thomas, et al.
Published: (2019-04-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
by: Minhinnick, A, et al.
Published: (2016)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
by: Thomas, Z, et al.
Published: (2014)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
by: Rowland, R, et al.
Published: (2012)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
by: Sheehan, S, et al.
Published: (2015)

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
by: Wajja, A, et al.
Published: (2023)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
by: Riste, M, et al.
Published: (2021)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
by: Sharon Sheehan, et al.
Published: (2015-01-01)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
by: Tameris, M, et al.
Published: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
by: Tameris, M, et al.
Published: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
by: Mcshane, H
Published: (2008)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.
by: Matsumiya, M, et al.
Published: (2014)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
by: Mcshane, H, et al.
Published: (2016)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
by: Matsumiya, M, et al.
Published: (2014)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
by: Harris, S, et al.
Published: (2011)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
by: Michael Riste, et al.
Published: (2021-04-01)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
by: Michele Tameris, et al.
Published: (2014-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
by: Rowland, R, et al.
Published: (2013)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
by: Harris, SA, et al.
Published: (2014)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Brookes, R, et al.
Published: (2008)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
by: Meyer, J, et al.
Published: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
by: Meyer, J, et al.
Published: (2013)

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
by: Wajja, A, et al.
Published: (2018)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
by: Mcshane, H, et al.
Published: (2005)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Roger H Brookes, et al.
Published: (2008-08-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
by: Wajja, A, et al.
Published: (2017)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
by: Scriba, T, et al.
Published: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
by: Roger H. Brookes, et al.
Published: (2011-01-01)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
by: Hawkridge, T, et al.
Published: (2008)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
by: Minassian, A, et al.
Published: (2011)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
by: Fletcher, H, et al.
Published: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
by: Anne Wajja, et al.
Published: (2017-05-01)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
by: White, A, et al.
Published: (2013)

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
by: Bunyasi, E, et al.
Published: (2017)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
by: Sander, C, et al.
Published: (2009)

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
by: Scriba, T, et al.
Published: (2012)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
by: Harris, SA, et al.
Published: (2014)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
by: Harris, S, et al.
Published: (2013)